4D Molecular Therapeutics (NASDAQ:FDMT) Receives Buy Rating from Jefferies Financial Group

Jefferies Financial Group restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report published on Monday morning,Benzinga reports. Jefferies Financial Group currently has a $21.00 target price on the stock, down from their previous target price of $40.00.

Several other research analysts have also issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Chardan Capital reaffirmed a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Wall Street Zen upgraded shares of 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Royal Bank Of Canada lifted their price target on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, March 19th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $31.25.

4D Molecular Therapeutics Trading Down 8.1%

NASDAQ FDMT opened at $8.57 on Monday. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34. The company has a market capitalization of $437.50 million, a price-to-earnings ratio of -3.54 and a beta of 2.99. The stock’s 50 day moving average is $8.95 and its two-hundred day moving average is $9.24.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.96. The business had revenue of $85.09 million during the quarter, compared to analysts’ expectations of $30.86 million. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%. On average, analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FDMT. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics during the 1st quarter worth about $39,000. Wexford Capital LP acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at about $41,000. Quadrature Capital Ltd acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at about $42,000. Farther Finance Advisors LLC raised its stake in shares of 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after acquiring an additional 2,674 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics in the first quarter worth about $46,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.